Based on a CNRS patented encapsulating process
Pearl Biosystems developed a proprietary method for creating 3D cultures along with a proprietary algorithm for image analysis that enables rapid phenotypic screening of organoid populations for drug discovery liquid pearls technology. The method and proprietary analysis software were developed by the team of Dr. Christian D. Muller at the CNRS, University of Strasbourg, France.
Pearl BioSystem’s assessment technology is based on numerical analysis of HCS imaging and tracking of EC50 per molecule evaluated. Each assay is personalized according to the features and protocol of the scientist’s project.
The aim is to improve your analysis and your decision-making while respecting your specific process.
Technology property differentiation
Zero gravity maintained in the pearl facilitate a rapid tumor growth and faster results feedback.
3D configuration is an access of the tested molecules to a maximum of cancerous cells.
Pearl refractive Index of 1,33 = to water, the optical transparency enables direct tumoroid analysis performance with a macroscope confocal or hologram to predict molecule efficiency in 4 to 8 days instead of 14 days with a mouse.
Due to kinetic and optical property, we follow the evolution of the organoids inside the pearl with our macroscopes to assess the impact of the molecule and thus better guide research, without having to perform an animal biopsy.
Solution in the pearl is a liquid medium that ensure a homogenous molecule diffusion.
Cost effective: our process objective is to select the most promising molecule before the In Vitro step, you check the molecule performance before animal testing. You reduce your animal cost steps; you focus only on the molecule with a higher degree of market access.
No need sterile environment: easy handling without risk of contamination and easy fusion between beads to facilitated cocultures, that implies lower lab cost operation.
Maximized gas exchange
Competitive market price: our validation tests up to n=7 allow the customer to reach a better control of the validation process during our analysis phases.
We offer an opportunity to be ready for coming regulation requirement on reduction of animal testing.
We use less than 1mg (Vs competing processes 1-15 grams) of material for the tests, the customer entrusts us with his molecule without risk of being copied.